for layman like me just a translation
The Phase II HERIZON trial evaluated HER-Vaxx, a B-cell peptide-based vaccine, in HER2-overexpressing advanced gastric cancer patients. The study showed a 40% overall survival (OS) benefit for patients receiving HER-Vaxx plus chemotherapy compared to chemotherapy alone. No additional toxicity from HER-Vaxx was observed. The vaccine induced strong HER2-specific antibody responses, which correlated with tumor reduction and improved OS. The results suggest HER-Vaxx could be a potential alternative to trastuzumab, especially when the latter is unavailable or not toleratedComparison of HER-Vaxx with Standard Care and Competing Products
Standard Care (Chemotherapy + Trastuzumab):
- Trastuzumab is the current standard for HER2-overexpressing advanced gastric cancer, combined with chemotherapy.
- Effectiveness: It has shown improvement in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone.
- Limitations: Possible toxicity and availability issues.
HER-Vaxx (HERIZON Trial):
- Combination: HER-Vaxx + chemotherapy.
- Results: 40% OS benefit, 20% PFS benefit, no additional toxicity. High HER2-specific antibody response, leading to tumor reduction.
- Potential: May substitute trastuzumab in cases of unavailability or toxicity.
Competing Products in Clinical Trials:
- Other HER2-targeted Therapies:
- Zanidatamab (ZW25): Dual HER2-targeted bispecific antibody; in clinical trials showing promising efficacy in HER2-positive cancers.
- Margetuximab: HER2-targeted monoclonal antibody; enhances antibody-dependent cellular cytotoxicity (ADCC) more effectively than trastuzumab.
- DS-8201 (Trastuzumab Deruxtecan): Antibody-drug conjugate showing significant efficacy in HER2-positive tumors.
- Forums
- ASX - By Stock
- Media Thread
for layman like me just a translationThe Phase II HERIZON trial...
-
- There are more pages in this discussion • 452 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $356.9M |
Open | High | Low | Value | Volume |
4.9¢ | 4.9¢ | 4.8¢ | $328.5K | 6.792M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
45 | 5443565 | 4.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.9¢ | 2171910 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
36 | 4613688 | 0.048 |
36 | 4066646 | 0.047 |
46 | 3070983 | 0.046 |
60 | 6170008 | 0.045 |
11 | 1951364 | 0.044 |
Price($) | Vol. | No. |
---|---|---|
0.049 | 1200533 | 2 |
0.050 | 4130537 | 15 |
0.051 | 6179811 | 13 |
0.052 | 2579418 | 10 |
0.053 | 1158504 | 8 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |